TITLE:
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

CONDITION:
HIV Infections

INTERVENTION:
Lopinavir/Ritonavir

SUMMARY:

      The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and
      effective in lowering the amount of HIV in the blood of patients who have been treated with
      more than 1 protease inhibitor (PI).
    

DETAILED DESCRIPTION:

      All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study.
      Patients take study medications for 48 weeks, during which time there will be 15 study
      visits. There is a possibility of a study extension after 48 weeks.
    

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV-positive.

          -  Have a viral load (level of HIV in the blood) of at least 1,000 copies/ml.

          -  Have been receiving stable (no changes) anti-HIV treatment that includes at least 1
             PI for at least 8 weeks prior to study entry.

          -  Have received more than 1 PI for at least 12 weeks each at some time in the past.

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Have had any active opportunistic (AIDS-related) infections within the past 30 days.

          -  Have ever received nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as
             delavirdine, nevirapine, or efavirenz.

          -  Have received certain medications.

          -  Are pregnant or breast-feeding.

          -  Abuse alcohol or drugs.
      
